Exparel - (266 mg/20 mL Injectable Suspension)

Generic Name	Bupivacaine Liposome	Innovator	Pacira Pharma
Dosage	266 mg/20 mL Injectable Suspension	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	EXPAREL is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (******* ******* ******** **.)	*** / *********	*** **, ****	******* ** ** / *** ** **	********	*** ****** "** ****" *******

Chronology Of Events

Exparel - (133 mg/10 mL ; Injectable Suspension)

Generic Name	Bupivacaine Liposome	Innovator	Pacira Pharma
Dosage	133 mg/10 mL ; Injectable Suspension	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	EXPAREL is indicated: • In patients 6 years of age and older for single-dose infiltration to produce postsurgical local analgesia • In adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (******* ******* ******** **.)	*** \ *********	*** **, ****	******* ** ** \ *** ** **	********	*** ****** "** ****" *******

Chronology Of Events